XKRX243070
Market cap225mUSD
Dec 24, Last price
27,800.00KRW
1D
1.83%
1Q
-3.64%
Jan 2017
-56.43%
IPO
-61.85%
Name
Huons Co Ltd
Chart & Performance
P/E
6.52
P/S
0.60
EPS
4,266.73
Div Yield, %
3.24%
Shrs. gr., 5y
0.54%
Rev. gr., 5y
10.93%
Revenues
552.01b
+12.11%
Net income
50.47b
+124.88%
CFO
52.14b
+62.86%
Dividend
Jun 27, 2024300 KRW/sh
Profile
Huons Co., Ltd. provides medical solutions for human health in Korea and internationally. The company offers oral solid form drugs, including circulatory system, metabolic, antipyretic, analgesic, anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, antibiotic, well-being, urogenital system, and other chemotherapeutic products; and injection products, such as anesthetic, antipyretic, analgesic, anti-inflammatory, skeletal muscle relaxant, antispasmodic, antihistamine, circulatory system, respiratory system, adrenocortical hormone, enzyme, mineral, solvent, calcium, hemostatic, antidote, antibiotic, metabolic, hyaluronic acid, well-being, anticoagulant, and other tissue cell system products. It also provides eye drop and bio products, as well as medical devices. The company was formerly known as Kwang Myung Pharm and changed its name to Huons Co., Ltd. in June 2003. Huons Co., Ltd. was founded in 1965 and is headquartered in Seongnam, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2014‑12 | |
| Income | |||||||||
Revenues | 552,006,502 12.11% | 492,386,811 12.70% | 436,911,389 7.43% | ||||||
Cost of revenue | 456,859,986 | 411,805,703 | 354,589,567 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 95,146,516 | 80,581,108 | 82,321,822 | ||||||
NOPBT Margin | 17.24% | 16.37% | 18.84% | ||||||
Operating Taxes | 12,724,943 | 17,649,081 | 10,278,247 | ||||||
Tax Rate | 13.37% | 21.90% | 12.49% | ||||||
NOPAT | 82,421,573 | 62,932,027 | 72,043,575 | ||||||
Net income | 50,472,995 124.88% | 22,444,027 -27.02% | 30,752,119 -44.67% | ||||||
Dividends | (10,646,486) | (6,455,269) | (5,873,566) | ||||||
Dividend yield | 2.26% | 1.87% | 1.05% | ||||||
Proceeds from repurchase of equity | (6,443,206) | 2,225,453 | |||||||
BB yield | 1.87% | -0.40% | |||||||
| Debt | |||||||||
Debt current | 59,760,718 | 35,065,267 | 70,836,815 | ||||||
Long-term debt | 70,098,433 | 72,005,114 | 8,738,228 | ||||||
Deferred revenue | 7,622,013 | 8,102,966 | 8,502,966 | ||||||
Other long-term liabilities | 2,524,462 | 1,546,027 | 1,499,405 | ||||||
Net debt | 7,475,653 | (24,727,539) | (37,005,400) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 52,143,053 | 32,017,643 | 55,592,925 | ||||||
CAPEX | (43,678,453) | (42,703,717) | (41,137,125) | ||||||
Cash from investing activities | 3,020,067 | (68,170,321) | 13,991,916 | ||||||
Cash from financing activities | (21,081,601) | 9,212,740 | (39,852,264) | ||||||
FCF | 14,449,322 | 34,128,347 | 31,528,057 | ||||||
| Balance | |||||||||
Cash | 80,330,184 | 84,621,345 | 70,126,696 | ||||||
Long term investments | 42,053,314 | 47,176,574 | 46,453,747 | ||||||
Excess cash | 94,783,173 | 107,178,579 | 94,734,873 | ||||||
Stockholders' equity | 265,055,048 | 226,321,918 | 206,687,240 | ||||||
Invested Capital | 368,397,072 | 284,587,416 | 250,867,131 | ||||||
ROIC | 25.24% | 23.51% | 31.18% | ||||||
ROCE | 20.54% | 20.25% | 23.38% | ||||||
| EV | |||||||||
Common stock shares outstanding | 12,270 | 11,831 | 11,778 | ||||||
Price | 38,400.00 31.73% | 29,150.00 -38.89% | 47,700.00 -15.10% | ||||||
Market cap | 471,178,752 36.62% | 344,874,233 -38.61% | 561,820,045 -8.69% | ||||||
EV | 486,646,083 | 327,039,670 | 532,565,185 | ||||||
EBITDA | 113,378,357 | 97,312,035 | 95,166,870 | ||||||
EV/EBITDA | 4.29 | 3.36 | 5.60 | ||||||
Interest | 2,503,079 | 3,157,253 | 2,685,617 | ||||||
Interest/NOPBT | 2.63% | 3.92% | 3.26% | ||||||